Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of G-CSF in treatment of dysimmunity of ITP patient

A patient and immune technology, applied in the application field of G-CSF in the treatment of immune abnormalities in patients with ITP, can solve the problem of unclear role of G-CSF

Inactive Publication Date: 2019-03-01
PEOPLES HOSPITAL OF HENAN PROV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of G-CSF in the immune abnormalities of ITP remains unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of G-CSF in treatment of dysimmunity of ITP patient
  • Application of G-CSF in treatment of dysimmunity of ITP patient
  • Application of G-CSF in treatment of dysimmunity of ITP patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0016] The subjects included 12 chronic ITP patients and 12 age- and sex-matched healthy controls. The diagnosis of chronic ITP is mainly based on the diagnostic criteria issued by the ITP International Working Group in 2009, and patients with other diseases related to ITP are excluded. None of the patients received hormone therapy. There were 5 males and 7 females, the median age was 49.5 years old (17-79 years old), and the median platelet count was 10.0×10 9 / L(0.4~19.6×10 9 / L). Of the 12 patients in this study, 5 (41.7%) patients were positive for antiplatelet antibodies. Table 1 shows the clinical characteristics of ITP patients.

[0017]

[0018] In Table 1, M means the sex is male; F means the sex is female.

[0019] Perform the following steps on the above research objects:

[0020] 1. Isolation, cultivation and experimental treatment of PBMCs Take 5ml of peripheral blood anticoagulated with heparin sodium, centrifuge at room temperature at 1500g for 15 minut...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new use of a drug, in particular to a G-CSF regulating the ratio of Th1 / Th2 cells of PBMCs in an ITP patient to treat ITP. In vitro experiments demonstrate that the G-CSF canreduce the Th1 / Th2 ratio in the ITP patient in a dose-dependent manner. The decrease in the ratio of T-bet / GATA-3 demonstrates that the G-CSF can reduce the Th1 / Th2 ratio indirectly. The study shows for the first time the potential treatment effect of the G-CSF on the ITP patient.

Description

technical field [0001] The present invention relates to the treatment of essential thrombocytopenia, specifically the application of G-CSF in the treatment of immune abnormalities of ITP patients. Background technique [0002] Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by thrombocytopenia and skin bleeding, accompanied by complex pathological features. Macrophages, CD8+ T cells, and autoantibodies can all destroy platelets and play an important role in the pathogenesis of ITP. However, helper T cells (Th) play an important switch role in mediating B cell antibody production. In addition, ITP is an autoimmune disease mainly characterized by Th1 polarization, and the degree of increased Th1 / Th2 ratio is negatively correlated with platelet count and disease severity. Therefore, reversing Th1 polarization and restoring the balance of Th1 / Th2 may play a potentially important role in the treatment of ITP patients. [0003] Th cells play a regul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/19A61P37/02A61P7/04
CPCA61K38/193A61P7/04A61P37/02
Inventor 葛菲孙恺张茵朱尊民
Owner PEOPLES HOSPITAL OF HENAN PROV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com